FHC
MRKR icon

First Horizon Corporation’s Marker Therapeutics MRKR Stock Holding History

First Horizon Corporation’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$0 Hold
12
– – ﹤0.01% 1156
2021
Q1 		$0 Buy
+12
New +$275 ﹤0.01% 1148

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Horizon Corporation's MRKR Position: Q2 2021 in Review

First Horizon Corporation held its Marker Therapeutics (MRKR) position steady in Q2 2021 at 12 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

First Horizon Corporation first reported a position in MRKR in Q1 2021 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

  • First Horizon Corporation held 12 shares of Marker Therapeutics worth $0 as of Q2 2021.
  • First Horizon Corporation left its Marker Therapeutics share count unchanged in Q2 2021.
  • Marker Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #1156 holding.
  • First Horizon Corporation first reported a position in Marker Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.